Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
06.06. | Tourmaline Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
27.05. | H.C. Wainwright maintains $50 target on Tourmaline Bio stock | 1 | Investing.com | ||
21.05. | Leerink raises Tourmaline Bio target to $54, affirms Outperform | 2 | Investing.com | ||
21.05. | Tourmaline Bio stock holds $63 target post-Ph2 data | 3 | Investing.com | ||
21.05. | BMO maintains $35 target on Tourmaline Bio, sees overreaction | 1 | Investing.com | ||
TOURMALINE BIO Aktie jetzt für 0€ handeln | |||||
20.05. | Tourmaline Bio shares fall on Phase 2 data; Schrödinger cuts staff | 46 | BioPharma Dive | ||
20.05. | Tourmaline Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
20.05. | Tourmaline Bio posts mid-stage data for anti-inflammatory agent | 1 | Seeking Alpha | ||
20.05. | Tourmaline Bio, Inc.: Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease | 146 | GlobeNewswire (Europe) | - Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo... ► Artikel lesen | |
19.05. | Tourmaline Bio wird morgen Ergebnisse der Phase-2-Studie veröffentlichen | 1 | Investing.com Deutsch | ||
19.05. | Tourmaline Bio to reveal Phase 2 trial results tomorrow | 1 | Investing.com | ||
19.05. | Tourmaline Bio, Inc.: Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 | 2 | GlobeNewswire (USA) | ||
02.05. | Talaris Therapeutics GAAP EPS of -$0.89 | 1 | Seeking Alpha | ||
02.05. | Tourmaline Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
02.05. | Tourmaline Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.05. | Tourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights | 329 | GlobeNewswire (Europe) |
- Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 - - Tourmaline... ► Artikel lesen | |
23.04. | Cantor Fitzgerald maintains Overweight on Tourmaline Bio stock | 1 | Investing.com | ||
10.04. | Truist cuts Tourmaline Bio price target to $63, maintains Buy | 2 | Investing.com | ||
14.03. | H.C. Wainwright raises Tourmaline Bio stock target to $50 | 3 | Investing.com | ||
13.03. | Tourmaline Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
INFLARX | 0,696 | -0,43 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
CSL | 131,64 | +0,41 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
COHERUS ONCOLOGY | 0,643 | +1,42 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
OCULAR THERAPEUTIX | 8,198 | +4,04 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 2,076 | +7,79 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
ORUKA THERAPEUTICS | 9,550 | +1,06 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody | Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two... ► Artikel lesen | |
SPERO THERAPEUTICS | 2,500 | -0,79 % | Alleviating the Pain of CRPS Gave Heather Her Life Back: The Spero Clinic's Role in the Recovery | Is it possible that a simple sound can hurt you? That the sound of a bird singing in the yard can make you scream out in pain? That's the reality of having CRPS. Here's how the Spero Clinic helped Heather... ► Artikel lesen | |
CIDARA THERAPEUTICS | 40,800 | -3,77 % | Cidara Therapeutics-Aktie +114%: Das Ende der Grippe? | Sharedeals-Trader dürfen die Sektkorken knallen lassen! Die Cidara Therapeutics-Aktie, seit Jahren immer wieder ein Kauftipp von SD mit exorbitanten Renditen, ging zum Wochenauftakt um sage und schreibe... ► Artikel lesen | |
PALVELLA THERAPEUTICS | 17,600 | -4,35 % | Palvella Therapeutics Inc.: Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% | Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026... ► Artikel lesen | |
NEXTCURE | 0,389 | -1,27 % | NextCure-Aktionäre genehmigen Vorstandswahlen und Reverse-Split-Vorschlag | ||
DIANTHUS THERAPEUTICS | 15,300 | -1,92 % | Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside |